Trials / Completed
CompletedNCT01284530
Evaluation of the Pharmacokinetics, Safety, and Tolerability of TPM XR as Adjunctive Therapy in Pediatric Subjects With Epilepsy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
Multidose, Open-label, Multi-center Study to examine the steady state pharmacokinetics of TPM XR, as well as, safety and tolerability of repeated oral dosing in pediatric subjects with epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TPM XR | Equivalent TDD in XR form, QD, Day 1-14 |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-01-27
- Last updated
- 2016-06-02
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01284530. Inclusion in this directory is not an endorsement.